Product Profile of Rituximab Injection with Binding Affinity Properties
Rituximab Injection with Binding Affinity Properties comprises of a genetically engineered chimeric murine or human monoclonal IgG1 kappa antibody that is directed against CD20 antigen. Rituximab Injection has a molecular weight of approximately 145 kD and features binding affinity for CD20 antigen of approximately 8.0 nM. Rituximab Injection is formulated in polysorbate 0.7 mg/mL, sodium chloride 9 mg/mL, sodium citrate dihydrate 7.35 mg/mL and water for injection. Rituximab Injection is. Rituximab Injection with Binding Affinity Properties maintain a pH of 6.5 and finds usage alone or in combination with other medicines for effectively treating non-Hodgkin`s lymphoma which is a type of cancer where it helps the immune system by destroying cancer cells.
Key Features of Rituximab Injection with Binding Affinity Properties
- Comprises of a genetically engineered chimeric murine or human monoclonal IgG1 kappa antibody that is directed against CD20 antigen
- Rituximab Injection has a molecular weight of approximately 145 kD and features binding affinity for CD20 antigen of approximately 8.0 Nm
- Rituximab Injection is formulated in polysorbate 0.7 mg/mL, sodium chloride 9 mg/mL, sodium citrate dihydrate 7.35 mg/mL and water for injection
- Rituximab Injection maintain a pH of 6.5 and finds usage alone or in combination with other medicines for effectively treating non-Hodgkins lymphoma which is a type of cancer where it helps the immune system by destroying cancer cells
- Used for treating chronic lymphocytic leukemia (CLL) cancer and when combined with methotrexate, it helps in treating symptoms of rheumatoid arthritis
